Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04464525
Other study ID # 20190370
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date December 18, 2020
Est. completion date November 27, 2026

Study information

Verified date July 2021
Source Cytokinetics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.


Description:

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 27, 2026
Est. primary completion date November 27, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Participant has provided GALACTIC-HF PTA informed consent prior to initiation of any study specific activities/procedures. - Participant has completed GALACTIC-HF. Exclusion Criteria: - Investigational product was permanently discontinued during GALACTIC-HF due to protocol-specified reason. - Female participant is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 5 days after the last dose of treatment. - Female participants of childbearing potential unwilling to use 2 acceptable methods of effective contraception during treatment with OM and for an additional 5 days after the last dose of treatment. - Female participants of childbearing potential with a positive pregnancy test assessed on day 1 by a urine pregnancy test. - Participant has known sensitivity to any of the products or components to be administered during dosing. - History or evidence of any clinically significant disorder, condition or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.

Study Design


Related Conditions & MeSH terms

  • Chronic Heart Failure With Reduced Ejection Fraction
  • Heart Failure

Intervention

Drug:
Omecamtiv mecarbil
Film-coated tablet administered orally.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cytokinetics

Outcome

Type Measure Description Time frame Safety issue
Other Participant incidence of serious adverse events and treatment emergent adverse events Targeted adverse events are those which lead to temporary or permanent discontinuation of OM, adverse events that are possibly related to OM or study procedures, and all adverse events of myocardial infarction, myorcardial ischemia, and ventricular arrhythmia, irrespective of seriousness and relationship to OM. Up to 252 weeks
Primary Number of participants administered omecamtiv mecarbil during the treatment period Primary analysis is based on the exploratory outcome measure. Up to 252 weeks
See also
  Status Clinical Trial Phase
Completed NCT02861534 - A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Phase 3
Completed NCT02226120 - Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction Phase 3
Recruiting NCT06148935 - An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
Active, not recruiting NCT05093933 - A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) Phase 3
Completed NCT04836182 - A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Recruiting NCT04983043 - Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure Phase 2
Completed NCT04840914 - A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 1
Completed NCT02768298 - Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Phase 4
Active, not recruiting NCT05974189 - The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
Recruiting NCT05553886 - S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction Phase 3
Completed NCT02900378 - randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure Phase 3
Recruiting NCT05658458 - A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction) Phase 4
Recruiting NCT05728502 - An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
Recruiting NCT06195930 - A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Active, not recruiting NCT06363110 - An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States